CELLGEN DIAGNOSTICS AND GENOMIC TESTING COOPERATIVE PARTNER TO ESTABLISH A NEW STANDARD IN CO-DEVELOPMENT OF COMPANION DIAGNOSTICS FOR CANCER THERAPIES Alliance will enable a faster and more rigorous approach to biomarker discovery and companion diagnostic co-development Irvine, CA—April 3, 2019—Cellgen Diagnostics, a leading precision diagnostics company, and Genomic Testing Cooperative (GTC), a pioneer in molecular testing, today announced a strategic collaboration to help accelerate global development of companion tests for various oncology therapeutics. The collaboration, between GTC’s Next Generation Sequencing (NGS), artificial intelligence (AI) based biomarker discovery service and Cellgen’s integrated companion diagnostics platform will provide the pharmaceutical industry a seamless integration of biomarker discovery, validation and development of in […]
Why not Stay in Touch…?
- Time Matters on Health Tests [TAT-NGS]
- Myelodysplastic Syndrome (MDS)
- Genomic Testing Cooperative Receives Medicare (Palmetto GBA) Coverage for two NGS Hematology Molecular Profiling Tests Including Liquid Biopsy for Hematologic Neoplasms
- Comprehensive PIK3CA Mutation Analysis
- The FDA has Approved Drugs for FGFR Abnormalities
acute myeloid leukemia Adult AI AML apoptosis B-Cell Lymphoma beta 2-Microglobulin Biological Biological Processes Biomarkers bone marrow BTK Case Study chemotherapy Clinically relevant CLL Congress Diseases DNA profiling enzyme inhibitors genetic profiling genomic testing gtc hematology ibrutinib Janus Kinase 2 Ki-67 Antigen leukemia liquid biopsy Lymphoid Malignancies Myeloid Malignancies ngs Non-Biological PLCγ2 press release Receptors resistance RNA sequencing signal transduction Study Population Technology and Procedures Therapies Thrombopoietin TKI Young Adult